View our summary of the key M&A, private equity and venture capital deals across the UK healthcare sector in July 2023 below.
Notable sector deals: July 2023
Acquisition of CA Case Management by HCML
Another successful acquisition for Apposite-backed rehabilitation and case management provider HCML
CA Case Management is a specialist provider of brain injury case management services and expert witness solutions across the south-east of England
The acquisition will bolster HCML’s case management offering across serious and catastrophic injury, in addition to expanding its geographical footprint
This is the second deal for HCML following Apposite’s investment in November 2021, as the business continues to effectively deploy its acquisition strategy
The broader case management sector continues to see interest from a range of acquirers such as HCML, Handl and Frenkel Topping
Acquisition of Bailey Instruments by the Marsden Group
A strategic addition for Marsden, the Alcuin Capital-backed manufacturer of medical weighing devices, with the acquisition of Manchester-based medical device specialists, Bailey Instruments
Bailey Instruments manufacture a range of single use and reusable medical devices and surgical instruments which are used in general surgery, podiatry, maternity and ENT
The acquisition will enhance Marsden’s international growth strategy, extending and diversifying its range of medical instruments
Since Alcuin’s investment in 2019, Marsden has grown revenues to over £8.2m and the addition of Bailey will significantly bolster this growth
IVC’s divestment of four practices to Perwyn
Following a CMA review, IVC has divested four veterinary practices to private equity investor Perwyn, and a further four practices to individual purchasers
The CMA’s continued intervention in the UK veterinary sector has stifled deal activity, particularly amongst the “Big 6” operators
We have previously alluded to the situation leaving an open door for a new platform, and Perwyn have clearly capitalised upon the opportunity to acquire a small group of practices (one would assume at a discounted price due to the forced sale) from which to expand
It will be fascinating to see how this situation develops, as the landscape for M&A across the veterinary sector has radically changed in a short period
Inuvi’s acquisition of Express Diagnostics
A significant deal for Inuvi, with the acquisition of Plymouth-based diagnostic services provider, Express Diagnostics
Express Diagnostics is the UK’s largest provider of remote holter analysis and ECG interpretation, in addition to providing audiology and health screening
Inuvi offers health assessments and phlebotomy visits through its network of mobile health practitioners, whilst conducting blood tests at its laboratory
The acquisition will broaden the group’s service offering, helping to establish Inuvi as a leading provider of expert diagnostic services
The deal highlights strong interest from acquirers in remote services which create efficiencies across both NHS and private diagnostic procedures
Healthcare market activity: July 2023
Private Equity Activity
Sub-sector | Target | Acquirer / Investor | Existing PE |
Case Management | CA Case Management | HCML (Apposite) | N/A |
Clinical Services | Express Diagnostics | Inuvi (Longacre) | N/A |
Clinical Services | Medica Group | IK Partners | N/A |
Medical Products | Bailey Instruments | Marsden Group (Alcuin) | N/A |
Medical Products | Great Bear Healthcare | Clinisupplies (KKR) | N/A |
Vet | 4 IVC practices | Perwyn | N/A |
Vet | Isabelle Vets | VetPartners (BC Partners) | N/A |
Venture Capital Activity
Target | Description | Lead Investor | Investment |
Capri Healthcare | Digital patient referral and automated triage solutions | Midven | £320k |
Entia | At-home blood testing for individuals undergoing cancer treatment | BGF Parkwalk | £16m |
Medmin Group | Concierge-style service for self-pay patients | Midven | £750k |
Thymia | Gamified AI tools to improve mental health assessments | Kodori Ventures | $2.7m |
uMed | Platform which helps to recruit patients into clinical studies and build evidence | Albion Capital | £9.8m |
Comments